Feb 25, 2021
Synthetic Biologics to Report 2020 Year End Operational Highlights and Financial Results on March 4, 2021
Dec 22, 2020
Synthetic Biologics Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol
Nov 24, 2020
Synthetic Biologics Announces Extension of Compliance Plan Period by NYSE American
Nov 16, 2020
Synthetic Biologics Engages A.G.P./Alliance Global Partners as Advisor to Assist in Evaluating Strategic Options
Nov 12, 2020
Synthetic Biologics Welcomes Senior Biotech Executive John Monahan, PhD, to Board of Directors
Nov 10, 2020
Synthetic Biologics Reports 2020 Third Quarter Operational Highlights and Financial Results
Nov 03, 2020
Synthetic Biologics to Report 2020 Third Quarter Operational Highlights and Financial Results on November 10, 2020
Oct 02, 2020
Synthetic Biologics Provides Update on Investigator-Sponsored Phase 2b Clinical Study of SYN-010 in IBS-C Patients
Aug 06, 2020
Synthetic Biologics Reports 2020 Second Quarter Operational Highlights and Financial Results
Jul 30, 2020
Synthetic Biologics Announces FDA Clearance of Investigational New Drug Application for SYN-020 Intestinal Alkaline Phosphatase (IAP)
Jul 29, 2020
Synthetic Biologics to Report 2020 Second Quarter Operational Highlights and Financial Results on August 6, 2020
Jun 30, 2020
Synthetic Biologics Announces Submission of IND Application to U.S. FDA for SYN-020 Intestinal Alkaline Phosphatase
May 27, 2020
Synthetic Biologics Enters into Exclusive Option to License Intellectual Property for Use of SYN-020 to Treat and Prevent Age-Related Metabolic and Inflammatory Diseases
May 05, 2020
Synthetic Biologics Reports 2020 First Quarter Operational Highlights and Financial Results
Jan 07, 2020
Synthetic Biologics Receives FDA Guidance at Type C Meeting for SYN-004 (ribaxamase) Phase 1b/2a Clinical Trial in Allogeneic HCT Recipients
Nov 27, 2019
Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan
Nov 04, 2019
Synthetic Biologics Reports Third Quarter 2019 Operational Highlights and Financial Results
Oct 28, 2019
Synthetic Biologics to Report 2019 Third Quarter Operational Highlights and Financial Results on November 4, 2019
Sep 26, 2019
Synthetic Biologics Strengthens U.S. Patent Coverage of SYN-010, Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
Aug 01, 2019
Synthetic Biologics to Report 2019 Second Quarter Operational Highlights and Financial Results on August 8, 2019